The Fed will raise interest rates by 25 basis points sometime around June because it wants to send a message, bond guru Bill Gross said.» Read More
What to expect from the earnings of Netflix, AK Steel, McDonald's and Simon Property Group, with CNBC's Melissa Lee, Courtney Reagan and Dominic Chu.
Discussing another delay for the Keystone XL pipeline, and the politics involved in moving the project forward, with John Hofmeister, former Shell Oil president.
Supporters of the Keystone Pipeline say it is critical to the North American oil boom, reports CNBC's Jackie DeAngelis. The Obama administration has added an additional delay in the program.
Discussing the pullback in biotech, with Paul Hickey, Bespoke Investment Group.
Sarepta Therapeutics CEO Chris Garabedian discusses the prospects for what he calls a "potential accelerated approval" for its Duchenne muscular dystrophy drug Eteplirsen.
Sarepta Therapeutics is developing a drug for Duchenne muscular dystrophy. Its CEO Chris Garabedian discusses challenges the drug Eteplirsen has faced before the FDA.
Sarepta Therapeutics got the go-ahead to file for approval of its experimental drug for Duchenne muscular dystrophy.
CNBC's Meg Tirrell reports on a new scientific discovery for the more than $1.7 billion U.S. business of in vitro fertilization. Robert Frank provides insight.
CNBC's John Harwood reflects on the last 25 years in D.C., as well as Texas Gov. Rick Perry's debate gaffe.
Both Monaco and Miami have soaring real estate prices. CNBC's Robert Frank reports the super rich are really transforming Miami.
Lululemon is having its first analyst day since its new CEO took over in January. Stacey Widlitz, CNBC retail analyst, provides perspective.
American oil companies are telling our U.S. state department they don't want a full-scale financial sanctions war, explains CNBC's Larry Kudlow. He makes the case for raising the value of the U.S. Dollar by 15 percent which he says will kill the price of oil.
CNBC's Steve Sedgwick provides an update from Geneva, where Ukraine talks are taking place.
Digging into what's really going on in the current trading action, with Art Hogan, Wunderlich Securities.
CNBC's Herb Greenberg explains why he thinks IBM should have sold off more today.
CNBC looks back on Mandy Drury's years with "Street Signs."
CNBC's Mary Thompson reports on the dark side of bitcoin.
Discussing the potential impact to gun sales after former NYC Mayor Mike Bloomberg announced he is spending $50 million on a gun safety group, with Brian Rafn, Morgan Dempsey Capital Management.
Hunter Keay of Wolfe Research, says there is no fundamental reason the airlines are off from their recent highs, and shares his top picks.
Many analysts still believe Twitter is overvalued after the stock's surge on its purchase of social data firm Gnip. CNBC's Morgan Brennan reports.